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The great discovery of microRNAs (miRNAs) has revolu-
tionized current cell biology and medical science. miRNAs 
are small conserved non-coding RNA molecules that 
post-transcriptionally regulate gene expression by targeting 
the 3’ untranslated region of specific messenger RNAs for 
degradation or translational repression. New members of the 
miRNA family are being discovered on a daily basis and 
emerging evidence has demonstrated that miRNAs play a 
major role in a wide range of developmental process includ-
ing cell proliferation, cell cycle, cell differentiation, metabo-
lism, apoptosis, developmental timing, neuronal cell fate, 
neuronal gene expression, brain morphogenesis, muscle dif-
ferentiation and stem cell division. Moreover, a large number 
of studies have reported links between alterations of miRNA 
homeostasis and pathological conditions such as cancer, psy-
chiatric and neurological diseases, cardiovascular disease, 
and autoimmune disease. Interestingly, in addition, miRNA 
deficiencies or excesses have been correlated with a number 
of clinically important diseases ranging from cancer to my-
ocardial infarction. miRNAs can repress the gene translation 
of hundreds of their targets and are therefore well-positioned 
to target a multitude of cellular mechanisms. As a con-
sequence of extensive participation in normal functions, it is 
quite logical to ask the question if abnormalities in miRNAs 
should have importance in human diseases. Great discov-
eries and rapid progress in the past few years on miRNAs 
provide the hope that miRNAs will in the near future have a 
great potential in the diagnosis and treatment of many 
diseases. Currently, an explosive literature has focussed on 
the role of miRNA in human cancer and cardiovascular 
disease. In this review, I briefly summarize the explosive cur-
rent studies about involvement of miRNA in various human 
cancers and cardiovascular disease.
[Immune Network 2011;11(3):135-154]
INTRODUCTION
The discovery of microRNAs (miRNAs), a new class of neg-
ative regulator that repress gene expression by pairing with 
their target messenger RNAs (mRNAs), has revealed a natural 
pathway for controling gene expression (1-3). There are hun-
dreds of miRNAs encoded in the human genome and thou-
sands of target mRNAs, which illustrates the important regu-
l a t o r y  r o l e s  o f  m i R N A s  i n  c e l l  development,  differentiation. 
proliferation and apoptosis pathways (4,5). It is not surprising 
that  deregulated miRNAs  have  been  involved  in  the  patho-
genesis of many human disease (2,6-8). The recent develop-
ment of technologies and compounds of identity and modu-
lated miRNAs has opened new avenues for diagnosis, prog-
nosis  and  therapeutic  applications  (6,9,10).
    miRNAs are found in almost all species: virus, plants, nem-
atodes, fly, fish, mouse, human, and are implicated in a wide 
array of cellular and developmental process (11). Extensive 
genome-wide expression profiling of cells and tissues in dif-
ferent  stages  of  development  or  differentiation,  metabolic 
conditions,  and  disease  models  using  miRNA  microarrays 
brought to the conclusion that unique miRNA profiles exist 
that are specific for the studied types of samples (1,11). These 
exciting  but  unexpected  findings  crystallized  the  hypothesis 
that genome-wide miRNA expression profiling could be used 
to  profile  tumors  based  on  their  origin  and  differentiation MicroRNAs in Human Cancers and Heart Disease
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state,  to  help  in  diagnostic,  prognosis,  and  for  the  use  of 
miRNAs in therapeutic (11,12). Abnormal patterns of hema-
topoietic-specific miRNAs have been found in different types 
of cancer and miRNA-based gene therapy is being considered 
as  a  potential  technology  of  choice  in  immunological  dis-
orders  and  cancer  (11).
    As  mentioned  above,  miRNAs  have  recently  emerged  as 
important regulators of gene expression. They were formerly 
thought to mainly repress the translation of target mRNAs, but 
it has recently been shown that the main function of miRNAs 
in mammalian system is to decrease target mRNA levels (13). 
Recent  evidence  also  suggests  that  the  number  of  unique 
miRNA genes in human exceed 1,000, and may be as high 
a s  2 0 , 0 0 0  a n d  i t  i s  e s t i m a t e d  t h a t  2 0 ∼30%  of  all  human 
m R N A  a r e  m i R N A  t a r g e t s  ( 1 4 ) .  A n d  s o ,  i t  i s  p r o b a b l e  t h a t  
most mRNAs are controlled by miRNAs to some extent. The 
expression of miRNAs is highly regulated and they are there-
fore well placed to function as immunomodulators (15). More 
recently, miRNA are also proving to be an important link be-
tween  the  innate  and  adaptive  immune  systems,  and  their 
dysregulation might have a role in the pathogenesis of vari-
ous  diseases  (1,2,15).
    Importantly, it has been increasingly reported that miRNAs 
are associated with disease. However, the pattern among the 
miRNA-disease association remains largely unclear. In order 
to dissect the patterns of miRN A-disease associations, Lu et 
al. performed a comprehensive analysis to the human miRNA 
disease  association  data,  which  is  manually  collected  from 
publication (16). They built a human miRNA association dis-
ease network. Interestingly, miRNAs tend to show similar or 
different  dysfunctional  evidence  for  the  similar  or  different 
disease  clusters,  respectively  (16).  In  addition,  they  also 
f o u n d  t h a t  t h e r e  i s  a  n e g a t i v e  c o r r e l a t i o n  b e t w e e n  t h e  t i s -
sue-specificity of a miRNA and the number of disease it asso-
ciated and that there is an association between miRNA con-
servation and disease (16). Furthermore, they uncovered that 
miRNAs associated with the same disease tend to emerge as 
predefined miRNA groups. These findings can not only pro-
vide help in understanding the association between miRNAs 
and human diseases, but also suggest a new way to identify 
novel  disease-associated  miRNAs  (16). 
    Their biological importance, initially demonstrated in can-
cer, was also more recently discovered in many other pathol-
ogies  like  Alzheimer’s  disease  (AD),  Parkinson’s  disease 
(PD),  viral  infections,  diabetes,  and  myopathies  (17).  They 
summarized miRNA profiling studies in human diseases and 
discuss the newly discovered link between miRNAs and drug 
response.  An  understanding  of  how  miRNAs  influence  the 
body’s  response  to  certain  drugs  and  how  these  affect  the 
expression of miRNAs, will be of key importance in develop-
ing  drugs  with  greater  safety  and  efficacy  (17).
    miRNA expression can be induced or expressed by a varie-
ty  of  stimuli  and  mechanisms.  These  stimuli  include  direct 
transcriptional  activation  or  repression  from  transcriptional 
enhancers, epigenetic modifications of the genome, genomic 
amplification  or  deletion,  cellular  stress  and  inflammatory 
stimuli (1,13,18). The effect of inducing or repressing miRNA 
expression can influence most biological processes, including 
c e l l  f a t e  s p e c i f i c a t i o n ,  c e l l  p r o l i f e r a t i o n ,  D N A  r e p a i r ,  D N A  
methylation and apoptosis and provide pro-inflammatory or 
anti-inflammatory  stimuli  (8,19).  The  biological  effect  of  a 
specific miRNA will depend on the cellular environment in 
which it is expressed its turnover rate and the target sequence 
that the miRNA can bind (1,13). Since a single miRNA can 
bind  its  target  sequence  with  imperfect  complementarity,  a 
specific miRNA can have many potential targets (1,13). This 
allows a single type of miRNA to simultaneously regulate the 
translation of many genes in multiple pathways. In this man-
ner, relatively small changes in miRNA expression can lead 
to modest changes in the levels of multiple proteins and col-
l e c t i v e l y  t h e s e  c a n  a d d  u p  t o  l a r g e  c h a n g e s  i n  b i o l o g y  
(20-22).  Selbach  et  al.  demonstrated  that,  in  addition  to 
down-regulating  mRNA  levels,  miRNAs  also  directly  repress 
translation of hundreds of genes and that a miRNA can, by 
direct  or  indirect  effects,  tune  protein  synthesis  from  thou-
sands of genes (20). miRNAs also have an essential role in 
both the innate and adaptive immune system. Proper miRNA 
expression is required for correct differentiation of immune 
c e lls  ( 23 ).  Im m un e  r es po ns es  are  sy mp ho n ie s o f mo le c ul ar 
and  cellular interactions,  with  each  player  doing  its part  to 
produce the composite behavior we see as effective host de-
fense,  or  when  discoordinated,  as  immunopatholgy  or  im-
munodeficiency (22). It is therefore not surprising that they 
have been implicated in various human diseases like cancer 
(2,19,24-28). cardiovascular diseases (5,6,29,30), neurological 
diseases  (7,31),  psychiatric  diseases  (10,32,33),  autoimmune 
diseases  (9,34-38),  skin  diseases  (39,40-42),  asthma  (43-45) 
and  microbial  infection  (1,46-50).  In  this  review,  I  briefly 
summarize the current knowledge of roles of miRNA in vari-
ous  human  cancers  and  cardiovascular  disease. MicroRNAs in Human Cancers and Heart Disease
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Figure 1. Modes of gene regulation by miRNAs. Diverse role of 
miRNAs, such as mRNA degradation, inhibition of translation, histone
modification, and DNA methylation. miRNAs not only regulate gene 
expression at the post-transcriptional level, but they are also capable
of modifying transcription (For the details, see Text).
Figure 2. Biological and cellular functions of miRNAs. miRNAs 
subserve multiple fundamental biological roles. Various miRNAs may
interact with thousands of different mRNA targets. Post-transcriptional
RNA editing may change mRNA target specificity (For the details, see
Text).
miRNA BIOGENESIS
All miRN As are processed and matured through  a  complex 
biogenesis  process  involving  multiple  protein  catalysis  ac-
cessory proteins, and macromolecular complexes following a 
coordinated  series  of  event.  The  reader  is  referred  to  ex-
cellent reviews for detailed discussion of miRNA biogenesis 
and  its  regulation  (2,51-54).  miRNAs  constitute  a  class  of 
small endogenous noncoding RNAs of 19-23 nucleotides that 
negatively  regulate  gene  expression  (51,52).  They  are  an 
abundant class of gene regulatory molecules in multicellular 
organisms and modulate the expression of many protein-cod-
ing  genes  (51,53,54).  They  are  transcribed  as  a  huge  dou-
ble-stranded primary transcript (pri-miR) by RNA polymerase 
II. Subsequently, nuclear enzyme Drosha (also known as ri-
bonuclease III) and Pasha convert this precursor into a dou-
ble-stranded miRNA precursor of ∼70 nulcleotide (pre-miR), 
which  is  next  transported  into  the  cytoplasm  by  a  mecha-
nisms involving the protein Exportin 5 (2,15,51,55). Finally, 
Dicer enzyme processes this precursor into the 22-nucleotide 
double-stranded miRNA. This duplex is then unwinded, and 
the leading strand ("guide strand"), one of the two strands, 
is  incorporated  into  the  RNA-induced  silencing  complex 
(RISC),  which  is  comprise  Agonaute  and  other  proteins 
(2,55,56). miRNAs incorporated in the RISC are able to bind 
to the 3’ untranslated region (UTR) of target mRNAs causing 
a block of translation or mRNA degradation depending on the 
level of complementarity (51,53). The other strand so-called 
"passenger strand" is degraded (2,40,51). Recent studies have 
clearly demonstrated that miRNAs play critical roles in several 
biologic  processes,  including  differentiation,  development, 
cell  growth,  and  apoptosis,  by  regulating  gene  expression 
through either the inhibition of mRNA translation or the in-
duction of its degradation (15,18,19). The analysis of human 
neoplasias of different tissue origins has shown deregulated 
miRNA  expression  (57,58).
miRNA FUNCTIONS 
As mentioned above, miRNAs recognize their target mRNAs 
based  on  sequence  complementarity  and  act  on  them  to 
cause the inhibition of protein translation by degradation of 
mRNA (51,59). It becomes evident that miRNA must be in-
volved in developmental timing, cell death, cell proliferation, 
hematopoiesis, patterning of nervous system and other nor-
m a l  c e l l u l a r  h o m e o s t a s i s  ( 5 1 , 6 0 , 6 1 ) .  A s  s h o w n  i n  F i g .  1 ,  i t  MicroRNAs in Human Cancers and Heart Disease
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Figure 3. miRNAs function as both tumor suppressor (including 
metastasis suppressor miRNA), and oncogene in breast cancer (For 
the details, see Text).
Figure 4. MicroRNAs are altered or induced by environmental 
chemicals, drugs and dietary components through epigenetic 
mechanisms and genetic polymorphisms including protein or miRNA
genes. Dietary components potentially influence fundamental cellular
processes involved in carcinogenesis and psychiatric disorders, 
including apoptosis, cell cycle control, angiogenesis, inflammation 
and DNA repair. These alteration can be caused by various 
mechanisms, including deletion, amplifications or mutations involving
miRNA loci, epigenetic silencing or dysregulation of transcription 
factors that target specific mRNA. Targeting miRNAs may provide 
insight into the common and unique pathways and mechanisms of 
the treatment. Elucidating more miRNAs and predicted targets may 
reveal novel therapies that modify plasticity cascades to restore 
function (For the details, see Text).
is  becoming  clear  that  miRNAs  is  only  regulated  gene  ex-
pression at the post-transcriptional level, but they are also ca-
pable of modifying chromatin (60,62,63). As shown in Fig. 
2,  participation  of  miRNAs  in  essential  biological  processes 
has  been  consistently  proven  (60,62-66),  such  as  cell  pro-
liferation  control  (miR-125b  and  let-7),  hematopoietic  B-cell 
lineage  fate  (miR-181),  B-cell  survival  (miR-15a  and 
miR-16-1), brain patterning (miR-430), pancreatic cell insulin 
secretion  (miR-375),  and  adipocyte  development  (miR-143). 
Furthermore, with the development of new techniques for ge-
nome-wide screening of miRNA expression, abnormal levels 
of  miRNA  were  identified  in  various  diseases  with  respect 
with  normal  counterpart  (58,59).  Given  the  importance  of 
miRNAs in regulating cellular differentiation and proliferation, 
it is not surprising that their misregulation is linked to cancer. 
In cancer, as shown in Fig. 3, miRNAs function as regulatory 
molecules, acting as oncogenes or tumor suppressors (67-71). 
I t  i s  i n t e r e s t i n g  t o  n o t e  t h a t  s o m e  m i R N A s  m a y  h a v e  d u a l  
functions  as  both  tumor  suppressor  and  oncogenes  (72). 
Amplification or over-expression of miRNAs can down-regu-
late tumor suppressors or other genes involved in cell differ-
entiation, thereby contributing to tumor formation by stimulat-
ing proliferation, angiogenesis, and invasion, i.e., they act as 
oncogenes  (59,65,66).  Similarly,  miRNAs  can  down-regulate 
different proteins with oncogenic activity, i.e., they act as tu-
mor  suppressor  (59,65,66).  Because  of  the  small  size  of 
miRNAs, loss-of-function or gain-of-function point mutations 
represent rare event (58). miRNA activity can be influenced 
by the reposition of other genes closed to promotors/regu-
latory regions of miRNAs (as is the case of miR-142s-cMYC 
translocation), or by the relocalization of an miRNA near oth-
er regulatory elements (64).  The  overall  effects  in  the case 
of miRNA inactivation is the over-expression of target mRNAs, 
while miRNA activation will lead to down-regulation of target 
mRNAs involved in apopotosis, cell cycle, invasion, or angio-
genesis  (63,64). 
    Very importantly, as shown in Fig. 4, miRNAs are altered 
or induced by both environmentally regulated early life devel-
opmental factors through epigenetic and miRNA mechanisms, 
and  genetic  polymorphisms  including  protein  or  miRNA 
genes (73). A growing body of experimental evidence sug-MicroRNAs in Human Cancers and Heart Disease
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gests  that  miRNAs  are  altered  by  environmental  chemicals 
such as cadmium, arsenic, dioxin, nickel, chronium, methyl-
m e r c u r y ,  b e n z e n e  a n d  a i r  p o l l u t i o n  ( 7 4 ) .  S u r p r i s i n g l y ,  e x -
posure to air pollution, particularly to particulate matter, has 
been associated with increased morbidity and mortality from 
c a r d i o r e s p i r a t o r y  d i s e a s e ,  a s  w e l l  a s  w i t h  l u n g  c a n c e r  r i s k  
(74). Additionally, it is interesting that a growing body of liter-
ature suggest that miRNAS can be altered by environmental 
and dietary factors such as genistein, curcumin (diferuloylme-
thane,  naturally  occurring  flavinoid  and  proapoptotic  com-
pound derived from the rhizome of Curcuma longa), retinoic 
acid,  folate  as  well  as  teratogen  and  ionizing  radiation 
(74-81). It has been known that miRNAs are altered by vinyl 
carbamate  (VC)  and  the  cancer  preventive  effect  of  crucif-
erous vegetables is attributed to their different phytochemical 
constituents (82). One of the most important anti-carcinogenic 
phytochemicals contained in these vegetables is indole-3-car-
binol (I3C), an enzymatic breakdown product of indole glu-
cosiniolates  (82).  Melkamu  et  al.  examined  if  the  chemo-
preventive  agent  I3C  reversed  VC-induced  deregulation  of 
miRNA levels in lung tissues of female A/J mice (82). They 
r e p o r t e d  t h a t  m i R N A s  a r e  d e r e g u l a t e d  d u r i n g  V C - i n d u c e d  
mouse lung tumorigenesis and their levels are modulated by 
I3C  (82).  A  recent  another  study  demonstrated  that  tera-
togen-induced  limb  dysmorphogenesis  may  be  associated 
with alteration in miR-34 and miR-125b expression and that 
p-53-independent  mechanisms  exist  contributing  to  tera-
togen-induced  activation  of  miR-34a  and  miR-34c:  some 
miRNAs act to protect embryos, whereas other miRNA boost 
a  teratogen-induced  process  of  maldevelopment  to  induce 
embryonic  death  (79).  Interestingly,  some  miRNAs,  which 
have been shown to change expression in response to cel-
lular stimulation, act as negative or positive feedback regu-
lators and they also may have key roles in mediating cross 
talk  between  inflammatory  mediators  (22).
    Interestingly, miRNAs are also regulated by stress and glu-
cocorticoids  and  during  the  cellular  stress  response  (73). 
miRNAs  have  the  capacity  to  change  from  translation  sup-
pressor  to  activator  by  forming  new  interactions  between 
miRNA/Argonaute  complexes  and  RNA-binding  protein  that 
alter their subcellular localization (73). Because of this modi-
fied activity, miRNAs could provide a pivotal role in media-
ting cellular adaptation to stress (73). In particular, miRNAs 
have been implicated in the way cells respond to oxidated 
stress, nutrient deprivation, and DNA damage (73). Chronic 
p s y c h o s o c i a l  s t r e s s  i s  k n o w n  t o  h a v e  a d v e r s e  p h y s i o l o g i c a l  
effects that contribute to cardiovascular disease, impaired im-
mune function, inflammatory disease, and neuronal function 
(73). Glucocorticoids are one of the prominent mediators of 
cellular  stress  effects  on  neural  function  and  behavior,  and 
are  known  to  structurally  alter  brain  cytoarchitecture  in  re-
gions that contribute to cognition, memory and emotion (73).
    As shown in Fig. 2, Nelson et al. summarized recent stud-
ies that have revealed intriguing novel aspects of miRNA func-
tion  (83):  1)  some  miRNA  are  edited  post-transcriptionally, 
and thus their targets can be profoundly altered, 2) some hu-
man miRNAs are targeted to the nucleus for as yet unknown 
reasons, 3) miRNA are shown to alter mRNA splicing and/or 
DNA methylation in trans, 4) miRNAs (like siRNAs) may rec-
ognize mRNAs outside of the 3’UTR, opening up new possi-
bilities  for  complex  gene expression  regulation, 5) viral-de-
rived miRNAs/siRNAs can play important roles in host cell bi-
ochemistry,  6)  under  some  circumstances,  miRNAs  can  in-
crease translation of targeted mRNAs, and 7) numerous cell- 
and  organism-level  functions  as  diverse  as  immunomodula-
tion, endocrine function, circadian rhythms, metabolic path-
ways, limb morphogenesis, and angiogenesis have been hy-
pothesized to be regulated by miRNAs. In addition, these al-
teration can be caused by various mechanisms, including de-
letion, amplifications or mutation involving miRNA loci, epi-
genetic silencing or dysregulation of transcription factors that 
target specific mRNA (25,58). As mentioned above and as will 
be  discussed  further,  recently,  a  growing  body  of  ex-
perimental evidence strongly suggests an unexpected mecha-
nism of miRNA involvement in various human diseases rang-
ing  from  cancer  to  psychiatric  diseases  (25,28). 
CANCER
There has been an explosion of literature focusing on the role 
of regulatory T (Treg) cells in cancer immunity and miRNAs 
are highly expressed in Treg cells (15,84-87). And, over the 
past several years it has become clear that alteration in the 
expression of miRNA genes contribute to the pathogenesis of 
most-if not all- human malignancies (25,58). These alteration 
can  be  caused  by  various  mechanisms,  including  deletions, 
amplifications or mutations involving miRNA loci, epigenetic 
silencing or the dysregulation of transcription factors that tar-
gets specific miRNAs (25,58). Because malignant cells show 
dependence on the dysregulated expression of miRNA genes, 
which in turn control or are controlled by the dysregulation 
of  multiple  protein-coding  oncogenes  or  tumor  suppressor MicroRNAs in Human Cancers and Heart Disease
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genes, these small RNAs provide important opportunities for 
the  development  of  future  miRMA-based  therapies  (24,88).
    Within the past few years, studies on miRNA and cancer 
have burst onto the scene. Profiling of the miRNome (global 
miRNA expression levels) has become prevalent, and abun-
dant miRNome data are currently available for various cancers 
(15,57,89). As mentioned, miRNA are a recently discovered 
class of small non-coding RNAs that regulate gene expression 
(2,24,90). Mature miRNA are the results of sequential process-
ing  of  pri-miRNAs  mediated  by  two  RNAse  III  enzymes, 
Drosha and Dicer (15,51-55). Mature miRNAs negatively regu-
late protein expression of specific mRNAs by either transla-
tional inhibition or mRNAs degradation (2,4,58). miRNA can 
contribute  to  cancer  development  and  progression  and  are 
differentially  expressed  in  human  cancers  (15,25,89).  Calin 
and Croce. also reported that miRNA-expression profiling of 
human tumors has identified signatures associated with diag-
nosis, staging, progression, prognosis and response to treat-
ment (58). From a large-scale miRnome analysis on 540 sam-
ples including lung, breast, stomach, prostate, colon and pan-
creatic tumors, Volinia et al. identified a solid cancer miRNA 
signature  composed  by  a  large  portion  of  over-expressed 
m i R N A s  ( 5 7 ) .  T h e y  r e p o r t e d  t h a t  a m o n g  t h e s e  m i R N A s  a r e 
s o m e  w i t h  w e l l  c h a r a c t e r i z e d  c a n c e r  a s s o c i a t i o n ,  s u c h  a s  
miR-17-5p,  miR-20a,  miR-21,  miR-92,  miR-106,  and  miR-155 
(57).  The  predict  targets  for  the  differentially  expressed 
miRNAs  are  significantly  enriched  for  protein-coding  tumor 
suppressor and oncogene. A number of the predicted targets, 
including the tumor suppressor RB1 (retinoblastoma 1) and 
TGFBR (transforming growth factor, beta receptor II) genes 
were  confirmed  experimentally  (57).  Their  studies  indicate 
that miRNAs are extensively involved in cancer pathogenesis 
of solid tumors and support their function as either dominant 
or  recessive  cancer  genes  (57).
    Importantly, miRNA deficiencies or excess have been corre-
lated with a number of clinically important diseases ranging 
from myocardial infarction to cancers (67). The loss or gain 
of miRNA function can be caused by a single point mutation 
in either the miRNA or its target or by epigenetic silencing 
o f  p r i - m i R N A  t r a n s c r i p t i o n  u n i t s  ( 6 7 ) .  I n t e r e s t i n g l y ,  a  h i g h -  
throughput analysis of miRNA expression in cancer demon-
strated that some miRNA are over-expressed in cancer, while 
others are markedly reduced in malignant tissue (67). These 
correlative data suggest that miRNAs function as both onco-
genes  and  tumor  suppressors  (67-71).  Numerous  studies  in 
cancer cell lines show a direct functional link between aber-
rant  miRNA  expression  and  particular  tumor  types  (58,67, 
69,91).  As  aforementioned,  recent  studies  also  show  that 
some miRNAs regulate cell proliferation and apoptosis proc-
esses that are important in cancer formation (69). By using 
multiple  molecular  technique,  which  include  Northern  blot 
analysis, real-time PCR, miRNA microarray, up- or down-ex-
pression of specific miRNAs, it was found that several miRNAs 
were  directly  involved  in  human  cancers,  including  lung, 
breast,  brain,  stomach,  liver,  colon,  prostate,  thyroid,  pan-
creas, ovary cancer and leukemia (4,19,67,69,92,93). In addi-
tion, some miRNAs may function as oncogene or tumor sup-
pressor (67,69-71). More than 50% of miRNA genes are lo-
cated in cancer-associated genomic regions or in fragile sites, 
suggesting that miRNAs may play a more important role in 
the pathogenesis of a limited range of human cancers than 
previously  thought  (67,71).  Interestingly,  over-expressed 
miRNA in cancers, such as miR-17-92, may function as onco-
gene and promote cancer development by negatively regulat-
ing tumor suppressor genes and/or genes that control cell dif-
ferentiation or apoptosis (69,91). Under-expressed miRNAs in 
cancers,  such  as  let-7,  function  as  tumor  suppressor  genes 
and may inhibit cancer by regulating oncogenes and/or genes 
that  control  cell  differentiation  or  apoptosis  (69,70,91). 
miRNA expression profiles may become useful biomarkers for 
c a n c e r  d i a g n o s i s  a n d  m i R N A  t h e r a p y  c o u l d  b e  a  p o w e r f u l  
tool for cancer prevention and therapeutics in not distant fu-
ture  (69,70,94,95).  Moreover, since  misregulation of miRNA 
has  been  associated  with  various  cancers,  the  identification 
of specific regulators of miRNAS will be helpful in developing 
new  therapeutic  agents.
BREAST CANCER
Interestingly, miRNA aberrant expression has been found in 
human  breast  cancer,  where  miRNA  signature  were  asso-
ciated with specific clinicobiological features (93). Compared 
with normal breast tissue, miRNAs are aberrantly expressed 
in  human  breast  cancer.  Overall  miRNA  expression  could 
clearly separate normal versus cancer tissues, with the most 
significantly  deregulated  miRNAs  being  miR-125b,  miR-145, 
m i R - 2 1 ,  a n d  m i R - 1 5 5  ( 9 3 ) .  I n t e r e s t i n g l y ,  T a v a z o i e  e t  a l .  
showed that restoring the expression of some miRNAs in ma-
lignant cells suppresses lung and bone metastasis by human 
cancer cells in vivo (96). Of these miRNAs, miR-126 restora-
tion reduces overall tumor growth and proliferation, whereas 
miR-335 inhibits metastatic cell invasion (96). They also re-MicroRNAs in Human Cancers and Heart Disease
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ported that miR-335 regulates a set of genes whose collective 
expression in a large cohort of human tumors is associated 
with  risk  of  distal  metastasis  and  that  miR-335  suppresses 
metastasis and migration through targeting of the progenitor 
cell transcription factor SOX4 and extracellular matrix compo-
nent tenascin C (96). Moreover, they demonstrated that ex-
pression  of  miR-126  and  miR-335  is  lost  in  the  majority  of 
primary breast tumors from patients who relapse, and the loss 
of expression of either miRNA is associated with poor distal 
metastasis-free  survival.  Thus,  they  noted  that  miR-335  and 
miR-126 are identified as metastasis suppressor miRNAs in hu-
man  breast  cancer  (96).
    Recently, miRNAs are thought to regulate invasion via di-
rect interaction with target genes within cells (26). A study 
showed that miR-17/20 cluster inhibit cellular migration and 
invasion  of  nearby  cells  via  heterotypic  secreted  signals  in 
breast cancer, indicating that the findings not only reveal an 
anti-invasive  function  of  miR-17/20 cluster in  breast  cancer, 
but also identify a heterotypic secreted signal that mediates 
the  miRNA  regulation  of  tumor  metastasis  (26). 
    As discussed, the presence of Treg cells in breast cancer 
marks an invasive phenotype and poor prognosis (97). In ad-
dition  to  their  immunosuppressive  role  in  antitumoral  re-
sponses,  CD4＋Treg  cells  contribute  to  mammary  tumor 
metastasis through the expression of receptor activator of nu-
clear factor-κB ligand (RANKL) and its receptor RANK (97). 
Tan et al. currently examined whether RANKL and RANK are 
involved  in  mammary/breast  cancer  metastasis  (97).  They 
found  that  tumor-infiltrating  Treg  cells  stimulate  mammary 
cancer  metastasis  through  RANKL-RANK  signalling  and  that 
CD4 Treg cells are the main products of RANKL in breast can-
cer tumors (97). They also reported that most RANK-produc-
ing cells expressed Foxp3 and that their results are consistent 
with the adverse impact of tumor-infiltrating CD4＋ or Foxp3＋ 
T cells on human breast cancer prognosis. These results sug-
gest that the targeting of RANKL-RANK can be used in con-
junction with the therapeutic elimination of primary breast tu-
mors  to  prevent  recurrent  metastastic  disease  (97).
PANCREATIC CANCER 
Pancreatic cancer is the leading cause of cancer-related death 
and  the  prognosis  for  pancreatic  cancer  is  the  worst  of  all 
cancers  with  high  mortality,  a  mortality/incidence  ratio  of 
0.99 (92). The incidence of pancreatic cancer in the United 
States is ∼9 per 100,000. These discouraging numbers, re-
flecting the increasing rates of incidence and death, are due 
to the lack of improvement in detection and diagnosis strat-
egies and the paucity of breakthroughs in treatment regimens 
(92). A miRNA expression signature has been identified that 
is associated with pancreatic cancer and this has been accom-
plished with the application of real-time PCR profiling of 200 
miRNA  precursors  on  specimens  of  human  pancreatic  ad-
enocarcinoma,  paired  benign  issue,  normal  pancreas,  pan-
creatitis and cell lines (92). Lee et al. (92) showed that one 
hundred miRNA precursors were aberrantly expressed in pan-
creatic cancer or desmoplasia, including miRNAs previously 
reported as differentially expressed in other human cancers 
(miR-155, miR-21, miR-221, and miR-222) as well as those not 
previously reported in cancer (miR-376a and miR-301). They 
also demonstrated that most of the top aberrantly expressed 
m i R N A s  d i s p l a y e d  i n c r e a s e d  e x p r e s s i o n  i n  t u m o r  a n d  t h a t  
three  of  the  top  differentially  expressed  miRNAs  (miR-221, 
miR-221, miR-301) were localized to tumor cells and not to 
stroma or normal acini or ducts (92). They noted that aber-
rant miRNA expression may offer new clues to pancreatic tu-
morigenesis and may provide diagnostic biomarkers for pan-
creatic adenocarcinoma (92). It is well established that many 
tumor  suppressor  genes  in  human  cancer  are  silenced  by 
chromatin  alterations,  including  promoter  methylation  and 
histone deacetylation (98). Lee at al. treated two human pan-
creatic  cancer  cell  lines  (MiaPACA-2  and  PANC-1)  with  the 
demethylating agent, 5-aza-2’-deoxycytidine or histone deace-
tylase inhibitor, trichostatin A, as well as the combination of 
the two (98). They assessed expression of miRNAs in control 
and  treated  cell  lines  using  a  custom  microarray  platform 
(98).  They  found  that  fourteen  miRNAs  were  up-regulated 
two-fold  or  greater  in  each  of  the  cell  lines  following  ex-
posure  to  both  chromatin-modifying  agent,  including  5 
miRNAs that were  in common  (miR-107,  miR-103, miR-29a, 
miR-29b and miR-320) to both MiaPACA-2 and PANC-1 (98). 
Enforced  expression  of  miR-107  in  the  cell  lines  was 
down-regulated in vitro growth, and this was associated with 
repression  of  the  putative  miR-107  target,  cyclin-dependent 
kinase  6,  thereby  providing  a  functional  basis  for  the  epi-
genetic inactivation of this miRNA in pancreatic cancer (98). 
Additionally,  pancreatic  ductal  adenocarcinoma  (PDAC)  is 
known for its very poor overall prognosis (99). Therefore, ac-
curate early diagnosis and new therapeutic modalities are ur-
g e n t l y  n e e d e d .  R e c e n t l y ,  u s i n g  3 7 7  f e a t u r e  m i R N A  a r r a y ,  
Szafranska  et  al.  investigated  miRNA  expression  in  normal 
pancreas,  chronic  pancreatitis,  and  PDAC  as  well  as MicroRNAs in Human Cancers and Heart Disease
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PDAC-derived cell lines (99). They found that the expression 
of miR-216 and miR-217 and lack of expression of miR-133a 
were identified as characteristic of pancreas tissue. The au-
thors  also  identified  26  miRNAs  most  prominently  mis-
regulated in PDAC. Their data provide novel insights into the 
miRNA-driven  pathophysiological  mechanisms  involved  in 
PDAC and offers new candidate targets to be exploited both 
for  diagnosis  and  therapeutic  strategies  (98).
    A recent study showed that pancreatic cancer tissues or cell 
lines have a unique miRNA profiling pattern at the individual 
basis  as  compared  with  relatively  normal  pancreatic  tissues 
or cells as well as pancreatitis tissue (100). This study also 
showed that eight miRNAs were significantly up-regulated in 
most  pancreatic  cancer  tissue  and  cell  lines,  including 
miR-196a,  miR-190,  miR-186,  miR-221,  miR-222,  miR-200b, 
miR-15b, and miR-95. Interestingly, the incidence of up-regu-
lation of these eight genes between normal controls and tu-
mor  cells  or  tissues  was  ranging  from  70%  to  100%  (100). 
Interestingly,  miR-21  is  relatively  over-expressed  in  glio-
blastoma multiforme, cervical cancer, beast cancer, and many 
other solid tumor types (55). Increased expression of miR-21 
appears to contribute to decreased apoptosis in malignant cell 
(55).  Similarly,  the  locus  containing  seven  miRNAs  of  the 
miR-17-92  polycistron  cluster  at  human  chromosome  13q31 
is amplified in a variety of B cell lymphomas, nasal NK/T cell 
lymphoma, and solid tumor (55). Conversely, some miRNAs 
can act as tumor suppressor, genes whose deletion or muta-
tion helps cell along the multi-step process of tumorigenesis 
(55). Circumstantial evidence for this possibility first emerged 
in early miRNA profiling experiments where tumor samples 
appeared to have lower overall levels of miRNA expression 
than  normal  tissue  sample,  both  in  human  clinical  material 
and  tissue  from  murine  cancer  model  (55). 
  In addition, tumor phenotype associated with extensive dis-
ease, such as invasion of surrounding tissue and metastasis, 
are also under the influence of miRNA controls (55). As men-
tioned,  experimental  evidence  has  shown  that  miRNAs  can 
play roles as oncogenes or tumor suppressor genes, suggest-
ing their contribution to cancer development and progression 
(69,70,91). Expression profile of human miRNA demonstrated 
that many miRNAs are deregulated in cancers and are differ-
entially expressed in normal tissues and cancers (69,70,91). 
Therefore,  miRNAs  profiling  is  used  to  create  signature  for 
a variety of cancer, indicating that the profile will help further 
establish  molecular  diagnosis,  prognosis  and  therapy  using 
miRNAs  (71). 
COLORECTAL CANCER (CRC)
Changes in the expression profiles of miRNAs have been ob-
served  in  a  variety  of  human  tumors,  including  CRC  (4). 
Several investigators have also described the ability of miRNA 
expression profiles to predict prognosis and response to se-
l e c t e d  t r e a t m e n t  i n  C R C  p a t i e n t s ,  a n d  s u p p o r t  d i a g n o s i s  o f  
CRC among cancer of unknown primary site (4). miRNA’s oc-
currence  has  been  repeatedly  observed  also  in  serum  and 
plasma, and miRNAs as novel minimally invasive biomarkers 
have  indicated  reasonable  sensitivity  for  CRC  detection  (4). 
Two approach are applied today to investigate the connection 
between  miRNAs  and  CRC  (4).:  functional  and  profiling 
studies. On one hand, miRNAs seem to regulate many known 
oncogenic  and  tumor  suppressor  pathways  involved  in  the 
pathogenesis of CRC. Many protein involved in key signaling 
p a t h w a y  o f  C R C ,  s u c h  a s  m e m b e r s  o f  W n t / β-catenin  and 
phosphatidylinositol-3-kinase  (PI-3-K)  pathways,  KRAS,  p53, 
extracellular  matrix  regulators  as  well  as  epithelial-mesen-
chymal transition (EMT) transcription factors, are altered and 
seem  to  be  affected  by  miRNA  regulation  in  CRC  (4).
    Recent studies have shown that, in cancer, expression of 
some miRNAs cells is silence in association with CpG island 
hypermethylation  (101).  To  identify  epigenetically  silenced 
miRNAs in CRC, Toyota et al. screened for miRNAs induced 
i n  C R C  c e l l s .  T h e y  f o u n d  t h a t  m i R - 3 4 b  a n d  m i R - 3 4 c ,  t w o  
components of the p53 network, are epigenetically silenced 
in CRC (101). They also found that the miR-34b/c CpG island 
is a bidirectional promoter which drives expression of both 
miR-34b/c and B-cell translocation gene 4 (BTG4). These re-
sults suggest that miR-34b/c and BTG4 are novel tumor sup-
pressors in CRC and that the miR-34b/c CpG island is a fre-
quent  target  of  epigenetic  silencing  in  CRC  (101).
    Recently,  Ng  et  al.  investigated  whether  plasma  miRNA 
could discriminate between patient with and without CRC and 
found  that  of  the  panel  of  95  miRNAs  analysed,  five  were 
up-regulated both in plasma and tissue sample and that all 
the five miRNAs were validated on the plasma of 25 patients 
with CRC and 20 healthy controls (102). They also found that 
both miR-173p and miR-92 were significantly elevated in the 
patients with CRC and that the plasma levels of these markers 
were  significantly  reduced  after  surgery  in  10  patients  with 
CRC  (102).  Further  validation  with  an  independent  set  of 
plasma sample indicated that miR-92 differentiates CRC from 
gastric cancer, inflammatory bowel disease (IBD) and normal 
subjects,  indicating  that  miR-92  can  be  a  potential  non-in-MicroRNAs in Human Cancers and Heart Disease
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vasive molecular marker for CRC screening (102). Recently, 
Wang et al. investigated the miR-31, miR-143 and miR-145 ex-
pression in 98 primary CRC specimens, along with the corre-
sponding normal mucosa specimens, and analyzed the rela-
tionship of their expression with clinicopathological features 
( 1 0 3 ) .  T h e i r  r e s u l t s  s h o w e d  t h e  m i R - 3 1  e x p r e s s i o n  w a s  
up-regulated in CRC compared to normal mucosa. They also 
showed that the miR-31 over-expression may be involved in 
the  development  and  progression  of  CRC  and  that  the 
miR-143 and miR-145 may play a certain role in the develop-
ment of colon and/or rectal cancers but not in progression 
of the disease (103). Recent reports have highlighted the on-
cogenic  aspects  of  miR-125b.  However,  the  clinical  sig-
nificance of miR-125b in gastrointestinal cancers has not been 
sufficiently  investigated.  Currently,  however,  Nishida  et  al. 
analyzed miR-125b expression in CRC cases (104). Evaluating 
miR-125b expression in 89 CRC cases, the authors found that 
miR-125b is directly involved in cancer progression and is as-
sociated with poor prognosis in human CRC (104). Their find-
ings suggest that miR-125b could be an important prognostic 
indicator for CRC patients. Huang et al. measured the levels 
of 12 miRNAs in plasma samples from patients with advanced 
colorectal  neoplasia  (carcinomas  and  advanced  adenomas) 
and  healthy  controls  using  real-time  RT-PCR  (105).  They 
found that plasma miR-29a and miR-92a have significant diag-
nostic value for advanced neoplasia. More importantly, these 
2 miRNAs also could discriminate advanced adenomas from 
controls (105). These data suggest that plasma miR-29a and 
miR-92a  have  strong  potential  as  novel  noninvasive  bio-
markers  for  early  detection  of  CRC.
    Importantly,  by  modulating  oncogenic  and  tumor  sup-
pressor pathways miRNAs could, in principle, contributes to 
tumorigenesis (90). And recurrent genetic and epigenetic al-
terations  of  individual  miRNAs  are  found  in  some  tumors 
(90). miRNAs that are amplified or over-expressed in cancer 
could act as oncogenes, and a number of putative oncogenic 
miRNAs have been proposed (2,55,58,67). An interesting case 
is represented by miR-155, which is up-regulated in several 
hematopoietic malignancies and tumors of the breast, lung, 
and  pancreas  (2,58,67,90).  Another  notable  member  of  the 
family of oncogenic miRNA is the miR-17-92 cluster (58,89,90).
    The role of miRNAs in tumorigenesis underscores their val-
ue  as  mechanism-based  therapeutic  targets  in  cancer  (95). 
Similarly,  unique  patterns  of  altered  levels  of  miRNA  pro-
duction provided fingerprints that may serve as molecular bi-
omarkers for tumor diagnosis, classification, prognosis of dis-
ease-specific outcomes and prediction of therapeutic response 
(94,95).  Recent  studies  demonstrated  that  the  best  charac-
terized  tumor-suppressor  miRNAs  are  miR-15a  and  miR-16 
and  that  B  cell  chronic  lymphocytic  leukemia  (CLL)  is  the 
most common adult leukemia in developed countries and is 
universally  associated  with  the  loss  of  chromosomal  region 
13q14 (58). The best characterized oncogenic miRNAs are the 
miR-17  cluster  which  comprises  a  group  of  six  miRNAs 
(miR-17-5p,  miR-18a,  miR-19a,  miR-20a,  miR-19b-1  and 
miR-92) at 13q31-32, a chromosomal region amplified in large 
B-cell lymphoma, follicular lymphoma, mantle cell lymphoma 
and  primary  cutaneous  B-cell  lymphoma  (95).
    The  "classic"  view  of  molecular  oncology  indicates  that 
cancer is a genetic disease involving tumor suppressor and 
oncogenic proteins (106). However, recent years, it has been 
demonstrated  that  miRNA  are  involved  in  human  tumori-
genesis, thus  revealing a  new layer  in the  molecular  archi-
tecture of human cancer (106). Gene expression studies re-
vealed  that  hundreds  of  miRNAs  are  deregulated  in  cancer 
cells and functional studies clarified that miRNAs are involved 
i n  a l l  t h e  m o l e c u l a r  a n d  b i o l o g i c a l  p r o c e s s e s  t h a t  d r i v e  t u-
morigenesis  (106).
LUNG CANCER 
Lung cancer is the leading cause of death from cancer in the 
world (107). miRNA have multiple functions in lung develop-
ment, and abnormal expression of miRNAs could lead to lung 
tumorigenesis  (107).  The  different  expression  profiles  of 
miRNAs in lung cancer, and the stability of miRNAs in serum, 
all together make them as new potential clinical biomarkers 
for diagnosis and prognosis (107). As mentioned, moreover, 
miRNAs may serve as either novel potential targets acting di-
rectly as oncogenes (e.g. miR-17-92 cluster) or directly ther-
apeutic molecules working as tumor suppressor genes (e.g. 
let-7 family) (107).  Twenty-three of  the 30  most highly ex-
pressed miRNAs shared in adult lung from mice and human. 
The miR-26, let-7, miR-29, miR-30 and miR-99 were expressed 
h i g h l y  i n  b o t h  s p e c i e s  ( 1 0 7 ) .  I m p o r t a n t l y ,  W a n g  e t  a l .  r e -
ported 123 miRNAs that may have potential roles in lung can-
cer (107). In the same paper, they reviewed dysregulation of 
various types of miRNA in development of lung and lung can-
cer  (107).
    In order to characterize the function of hsa-miR-125a-3p/5p 
in  invasion  and  metastasis  of  non-small  cell  lung  cancer 
(NSCLC),  Jiang  et  al.  investigated  the  relationship  between MicroRNAs in Human Cancers and Heart Disease
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hsa-miR-125a-3p/5p expression and lymph node metastasis in 
NSCLC  tissue  (108).  They  found  that  hsa-miR-125a-3p  and 
hsa-miR-125a-5p play distinct roles in regulation of invasive 
and  metastatic  capabilities  of  lung  cancer  cells  and  lymph 
node  metastasis  in  NSCLC,  indicating  that  miR-125a  family 
members play a important role in the development of NSCLC 
(108). As discussed, miRNA have been recently implicated in 
several carcinogenic processes, where they can act either as 
oncogenes or as tumor suppressors (67,68). This is the case 
in  lung  cancer,  i.e.  the  leading  cause  of  cancer  death  in 
Western countries, in which about 40-45 miRNAs have been 
found to be aberrantly expressed, thereby constituting a spe-
cific miRNA signature (89). Some transcript of the let-7 family 
that  are  significantly  down-regulated  in  lung  tumors  have 
been identified as tumor suppressors through their ability to 
control several oncogenic pathway, including the RAS path-
way  (89). 
    The pattern of miRNA expression can be correlated with 
cancer  type,  stage,  and  other  clinical  variables,  so  miRNA 
profiling can be used as a tool for cancer diagnosis and prog-
nosis (109). miRNAs play roles in almost all aspects of cancer 
biology, such as proliferation, apoptosis, invasion/metastasis, 
and  angiogenesis.  It  is  expected  that  more  miRNAs  will 
emerge as players in the etiology and progression of cancer 
(109).
GASTRIC CANCER 
Recent studies have shown that some miRNAs play roles as 
tumor suppressor or oncogene in gastrointestinal cancer and 
that miRNA expression is regulated by different mechanisms 
including  transcription  factor  binding,  epigenetic  alteration, 
and  chromosomal  abnormalities  (18,19,90).  miRNA  ex-
pression profiling may be powerful clinical tool for cancer di-
agnosis and regulation of miRNA expression could be a novel 
strategy for chemoprevention of human gastrointestinal can-
cer (110). To study the role of miRNAs in gastric cancer, Yao 
et  al.  analyzed  the  expression  profile  of  847  miRNAs  in 
Chinese patients with gastric cancer (111). The results from 
the  miRNA  microarray  analysis  were  validated  by  real-time 
RT-PCR. They found that a total of 24 miRNAs with a more 
than 2-fold change were differentially expressed between nor-
mal  gastric  tissue  and  gastric  cancer  (111).  Of  these,  22 
miRNAs, including miR-223, miR-106b, miR-147, miR-34a and 
others, were significantly up-regulated in gastric cancer, whe-
reas only miR-638 and miR-378 were significantly down-regu-
l a t e d  i n  g a s t r i c  c a n c e r  c o m p a r e d  t o  n o r m a l  g a s t r i c  t i s s u e  
(111). These results show that miRNAs are deregulated in gas-
tric cancer, suggesting the involvement of these genes in the 
development  and  progression  of  gastric  cancer. 
    Interestingly,  a  recent  study  showed  that  miR-21  is  con-
sistently up-regulated in solid human cancers, including the 
stomach,  as  compared  with  matching  noncancerous  tissue 
(48). Direct targets of miR-21 have been identified, with all 
of them being tumor suppressors. miR-21 was over-expressed 
in gastric cancer tissue sample and cell lines, as well as in 
chronically Helicobacter pylori-infected gastric epithelium tis-
sue,  as  opposed  to  noninfected  tissue  (48).
    With the capacity of miRNA to alter the survival and death 
of T and B cells, control over miRNA expression is essential 
to  prevent  adaptive  immune  cells  from  unregulated  pro-
liferation (24). miRNA can act both as ‘oncomirs’ and tumor 
suppressors, and thus dysregulation of miRNA in lymphocytes 
can cause malignancies (24,67,68). With strong evidence of 
miRNA-mediated control over T cell and B cell development 
and well-established roles in the regulation of genes control-
ling apoptosis and the cell cycle, it is not surprising that there 
is growing evidence for a causative role of miRNA in the de-
velopment  of  malignancies  of  the  adaptive  immune  system 
(24). Analysis of miRNA expression profiles has demonstrated 
altered  expression  in  numerous  hematologic  malignancies 
(24). The miRNA signature identified from these clinical stud-
ies have potential value as prognostic parameters for cancer 
progression. Futhermore, functional characterization of these 
miRNA  may  provide  insights  into  the  potential  of  manipu-
lation selective miRNAs as a novel therapeutic means to treat-
ment  of  hematologic  cancer  (24,112).  The  non-random  ge-
nomic distribution of miRNA, with tenfold enrichment in frag-
ile  sites,  suggests  that  at  least  some  of  these  expression 
changes  will  be  causative  in  tumor  development  (113).  To 
date,  many  miRNAs  with  oncogenic  activity  in  hematologic 
malignancies have been reported. These so-called ‘oncomirs’ 
such as the miR-17∼92 cluster, miR-21 and miR-155 are often 
found over-expressed in malignant tissues. For example, the 
mir-17∼9 2  c l u s t e r  i s  a  t a r g e t  o f  g e n o m i c  a m p l i f i c a i o n  o f  
13q31 that occurs in Burkitt’s lymphoma, diffuse large B-cell 
lymphoma  (DLBCL),  mantle  cell  lymphoma  and  follicular 
lymphoma  (114).  In  addition  to  the  miR-17∼92  cluster, 
miR-155 is one of the oncomirs which has been well charac-
terized in the adaptive immune system in both healthy devel-
opment  and  malignancy,  including  B  cell  lymphoma, 
Hodgkin’s lymphoma, DLBCL and Burkitt’s lymphoma (115). MicroRNAs in Human Cancers and Heart Disease
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In  contrast  to  the  oncomirs  described  above,  other  miRNA 
function  as  potent  tumor  suppressors.  The  loss  of  such 
miRNAs are frequently associated with T cell and B cell lym-
phoma  and  leukemia  (115).  One  example  is  miR-15a  and 
miR-161, two miRNA clustered in the 13q14 region. In more 
than  50%  of  CLL  patients,  this  region  was  found  deleted 
(116). Similarly, miR-29 and miR-181 are down-regulated in 
chronic  lymphocytic  leukemia  (CLL)  and  have  both  been 
shown to function as tumor suppressor. These miRNAs nor-
mally  suppress  proliferation  by  targeting  pro-survival  and 
pro-proliferation  genes  including  BCL-2,  TCL-1,  MCL-1  and 
CDK6  (117). 
    Recent studies have shown that miRNAs have unique ex-
pression profiles in cells of the innate and adaptive immune 
systems and have pivotal roles in the regulation of both cell 
development  and  functions  (2,15).  Furthermore,  when 
m i R N A s  a r e  a b e r r a n t l y  e x p r e s s e d  t h e y  c a n  c o n t r i b u t e  t o  
pathological conditions involving the immune system, such as 
c a n c e r  a n d  a u t o i m m u n i t y  ( 2 , 1 5 ) .  A s  d i s c u s s e d ,  m i R N A s  d i -
rectly modulate the concentration of many regulatory proteins 
that are required for normal development and function of the 
immune system. These proteins have been linked to immuno-
logical disease, in which the miRNAs are found to be mutated 
or their expression levels dysregulated, consequently trigger-
ing altered or impaired function (15,113). miRNA levels are 
also  dysregulated  in  diseases  of  immunological  origins  and 
many are known to be encoded near fragile sites in the ge-
nome (113). They have also been shown to be useful as diag-
nostic and prognostic indicators of disease type and severity.
    Acute  inflammatory  response  is  usually  beneficial,  espe-
c i a l l y  i n  r e s p o n s e  t o  m i c r o b i a l  i n f e c t i o n  a n d  t i s s u e  d a m a g e 
( 1 1 8 ) .  A  w e l l - r e g u l a t e d  i n f l a m m a t o r y  r e s p o n s e  c a n  a l s o  b e  
anti-tumorigenic and have a role in tumor suppression (118). 
Chronic inflammation and infection, however, is detrimental 
and, among other deleterious effects, will frequently predis-
pose cells for an oncogenic transformation (25). Key mediator 
of inflammation-induced cancer include nuclear factor kappa 
B  (NF-κB),  reactive  oxygen  and  nitrogen  species,  inflam-
matory  cytokines,  prostaglandins  and specific miRNAs (25). 
The potential to therapeutically regulate miRNA levels may of-
fer new avenues for cancer treatment and possibly in regulat-
ing the immune system. Inhibiting oncogenic miRNA or re-
introduction of tumor suppressor miRNAs may serve as useful 
strategies to treat cancer (4,18). Reintroduction of tumor sup-
pressor miRNAs can cause apoptosis or senescence in malig-
nant  cell  and  provide  new  avenues  for  developing  cancer 
therapeutics (4,18). A recent study clearly demonstrated this 
potential in mouse models of hepatocelluar carcinoma (HCC) 
patients (119). It has been shown that mi-26a is a tumor sup-
pressor  miRNA  that  is  reduced  in  HCC  and  that  decreased 
levels of miR-26a have been associated with poor prognosis 
and predictive to the therapeutic response to IFNα in HCC 
patients (25,119). Within the next several years, we will know 
if  miRNA-based  therapeutics,  alone  or  in  combination  with 
other modalities, will be clinically useful treatment for various 
cancers  and  immune  system  disorders.
THYROID CANCER 
A recent study investigated the expression patterns of miRNA 
in all major types of thyroid tumors, including tumors carrying 
distinct oncogenic mutations, and the utility of miRNA profil-
ing for the preoperative diagnosis of thyroid nodules (120). 
It  was  reported  that  a  set  of  seven  miRNAs  (miR-187, 
miR-221, miR-222, miR-146b, miR-155, miR-224, and miR-197) 
were  most  differentially  over-expressed  in  thyroid  tumors 
(120). Moreover, it was demonstrated that various histopatho-
logical types of thyroid tumors have distinct miRNA profiles, 
which  further  differ  within  the  same  tumor  type,  reflecting 
specific oncogenic mutations (120). These results may suggest 
that a limited set of miRNAs can be used diagnostically with 
high accuracy to detect thyroid cancer in the surgical and pre-
operative  samples  (120).
    T h e  t h y r o i d  g l a n d  i s  c o m p o s e d  o f  t w o  d i s t i n c t  h o r -
mone-producing cell types: follicular cells and parafollicular 
C - c e l l s  ( 1 9 ) .  F o l l i c u l a r  c e l l s ,  p r e s e n t  i n  t h e  m o n o l a y e r  e p i -
thelium, are responsible for iodine uptake and thyroid hor-
mone synthesis. C-cell are intrafollicular or parafollicular cells 
that are responsible for the production of the calcium-regulat-
ing hormone calcitonin (19). The majority of the thyroid tu-
mors (more than 95%) are derived from the follicular cells, 
while a minority (3%), called medullary thyroid carcinomas, 
are C-cell derived carcinomas (19). Thyroid tumors are of two 
types (19).: benign and malignant. Benign tumors are princi-
pally represented by adenomas, while malignant tumors are, 
in most cases, carcinomas. Thyroid carcinomas are one of the 
most  common  malignancies  of  the  endocrine  system. 
Follicular cell-derived carcinomas are commonly divided into 
well-differentiated thyroid carcinoma (WDTC), poorly differ-
e n t i a t e d  t h y r o i d  c a r c i n o m a  ( P D T C ) ,  a n d  u n d i f f e r e n t i a t e d  
types  depending  on  various histological  and  clinical  factors 
(19). WDTCs include papillary thyroid carcinoma (PTC) and MicroRNAs in Human Cancers and Heart Disease
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follicular  thyroid  carcinoma  (FTC)  types  (reviewed  in  19). 
Some years ago, several studies were undertaken to analyzed 
the expression of miRNAs in thyroid carcinoma to evaluated 
a possible role of their deregulation in the process of carcino-
genesis (19). These studies showed an aberrant miRNA ex-
pression profile that distinguishes uneqivocally among PTC, 
ATC  (anaplastic  thyroid  cancer),  and  normal  thyroid  issue. 
These  studies  also  demonstrated  that  miR-221  and  miR-222 
cluster play a significant role in thyroid carcinoma cell pro-
liferation  and  that  miR-221  and  miR-222  are  able  to  impair 
tumor  necrosis  factor-related  apoptosis  inducing  ligand 
(TRAIL)-dependent apoptosis by inhibiting the expression of 
key  functional  protein  (19).  Moreover,  the  studies  indicate 
that miR-222 plays an important role in cancer cell invasion 
(19).
OVARIAN CANCER 
As mentioned, miRNAs are emerging as important regulators 
of cancer-related process. A recent study showed that miR-9 
is down-regulated in human ovarian cancer relative to normal 
ovary, and over-expression of miR-9 suppresses cell growth 
in  vitro  (121).  Furthermore,  the  3’UTR  of  NF-kB1  is  found 
to be regulated directly by miR-9, demonstrating that NF-kB1 
is a functionally important target of miR-9 in ovarian cancer 
cells. When miR-9 is over-expressed in ovarian cancer cells, 
t h e  m R N A  a n d  p r o t e i n  l e v e l s  o f  N F - κB 1  a r e  b o t h  s u p -
pressed, whereas inhibition of miR-9 results in an increase the 
NF-κB1 expression level (121). Ovarian cancer tissues dis-
play significantly low expression of miR-9 and a high level 
of NF-κB1 compared with normal tissues, indicating that reg-
ulation of NF-κB1 by miR-9 is an important mechanisms for 
miR-9  to  inhibit  ovarian  cancer  (121). 
  Most ovarian cancer patients are diagnosed at an advanced 
stage (67%) and prospects for significant improvement in sur-
vival reside in early diagnosis (122). Tumors actively release 
exosomes into the peripheral circulation and the association 
of  miRNA  with  circulating  tumor-derived  exosomes  were 
demonstrated (122). These results suggest that miRNA profil-
in g  o f ci rc ul at in g  t um o r e x so m es  c ou ld  p ot e nt ia lly  b e  u se d 
as surrogate diagnostic markers for biopsy profiling, extend-
ing  its  utility  to  screening  asymptomatic  populations  (122).
PROSTATE CANCER 
A recent study showed that miR-15a and miR-16-1 cluster tar-
g e t s  e n c o d i n g  c y c l i n  D 1 ( C C N D 1 )  a n d  W N T 3 A ,  w h i c h  p r o -
motes  several  tumorigenic  features  such  as  survival,  pro-
liferation  and  invasion  (123). I n  c a n c e r  c e l l s  o f  a d v a n c e d  
prostate tumors, the miR-15a and miR-16 level is significantly 
decreased,  whereas  the  expression  of  BCL2,  CCND1  and 
WNT3A is inversely up-regulated (123). Delivery of antago-
mirs specific for miR-15a and miR-16 to normal mouse pros-
tate  results  in  marked  hyperplasia,  and  knockdown  of 
miR-15a  and  miR-16  promote  survival,  proliferation  and  in-
vasiveness of untransformed prostate cells, which become tu-
morigenic  in  immunodeficient  NOD-SCID  mice  (123).  Con-
vertsely, reconstitution of miR-15a and miR-16 expression re-
sults  in  growth  arrest,  apoptosis  and  marked  regression  of 
prostate tumor xenografts (123). The authors proposed that 
miR-15a and miR-16 act as tumor suppressor genes in pros-
tate cancer through the control of cell survival, proliferation 
and  invasion.  These  findings  have  therapeutic  implications 
and may be explored for future treatment of prostate cancer 
(123). Several miRNAs have been implicated as tumor sup-
pressors  based  on  their  physical  deletion  or  reduced  ex-
pression  of  human  cancer.  The  miR-15a-16-1  cluster  has  re-
cently  emerged  as  an  excellent  candidates  for  the  long 
sought-after tumor suppressor gene on 13q14 (24,27,68,89,109). 
The tumor suppressor activity of miR-15a-16-1 is not limited 
to B cells (2,124). More than 50% of human prostate cancers 
carry  a  deletion  of  13q14.  Accordingly,  a  recent  study  has 
shown  that  inhibition  of  miR-15a  and  miR-16  activity  leads 
to hyperplasia of the prostate in mice and promotes survival, 
proliferation, and invasion of primary prostate cells in vitro 
(123). In addition, the therapeutic potential of reconstituting 
expression of this cluster was illustrated by the significant re-
gression of prostate tumor xenografts upon intra-tumoral de-
livery of miR-15a and miR-16-1 (90,109). Recently, Zaman et 
al. investigated the expression and functional significance of 
miR-145 in prostate cancer. They found that one of the gene 
significantly up-regulated by miR-145 over-expression is the 
proapoptotic gene TNFSF 10 (125). Therefore, modulation of 
miR-145 may be an important therapeutic approach for the 
management  of  prostate  cancer.
    Cancer stem cells (CSCs), or tumor-initiating cells, are in-
volved in tumor progression and metastasis, and miRNAs reg-
ulate both normal and CSCs (27). CSCs in many tumors have 
been  identified  using  the  adhesion  molecule  CD44  (27).  A 
current studies showed that miR-34a, a p53 target, was un-
der-expressed in CD44＋ prostate cancer cells purified from 
xenograft and primary tumors and that enforced expression MicroRNAs in Human Cancers and Heart Disease
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of miR-34a in bulk or purified CD44＋ prostate cancer cells 
inhibited  clonogenic  expansion,  tumor  regeneration,  and 
metastasis (27). In contrast, expression of miR-34a antagomirs 
in CD44-prostate cancer cells promoted tumor development 
and  metastasis.  Interestingly,  systemically  delivered  miR-34a 
inhibited prostate cancer metastasis and extended survival of 
tumor-bearing mice, indicating miR-34a is a key negative reg-
ulator  of  CD44＋ prostate  cancer  cells  and  established  a 
strong rationale for developing miR-34a as a novel therapeutic 
agent  against  prostate  CSCs  (27).
    Importantly and interestingly, recent evidence indicates that 
dietary factors play an important role in the process of pros-
tate carcinogenesis through modulation of miRNA expression 
(75). Epidemiological data suggest that the rates of clinically 
significant prostate cancer are 15-fold higher in men from the 
United States than in men from Asian countries, attributable 
to the fact that Asian diet comprise a significant portion of 
soybean-enriched  foods  (75).  Genistein,  an  isoflavone  iso-
lated from soybean, has been found to be a potent antitumor 
agent  which  has  the  capacity  to  antagonizes  estrogen-  and 
androgen-mediated signaling pathways, possesses antioxidant 
properties,  and  is  a  potent  inhibitor  of  angiogenesis  and 
metastasis  (75).
HEPATOCELLULAR CARCINOMA (HCC)
Infection of human liver with HBV and HCV induces the de-
velopment of chronic hepatitis (CH), cirrhosis, and in some 
instances HCC (126). Ura et al. measured the expression of 
188  miRNAs in  liver tissues  obtained  from 12  patients with 
HBV-related  HCC  and  14  patients  with  HCV-related  HCC 
(126). They found that out of the 31 miRNAs associated with 
disease state, 17 were down-regulated in HCC, which up-reg-
ulated  cancer-associated  pathway  such  as  cell  cycle,  adhe-
sion,  proteolysis,  transcription,  and  translation;  6  miRNAs 
were up-regulated in HCC, which down-regulated anti-tumor 
immune response, suggesting miRNAs are important media-
tors of HBV and HCV infection as well as liver disease pro-
gression, and therefore could be potential therapeutic target 
molecules  (126).
LEUKEMIA 
miRNA expression profiles can be used to distinguish normal 
B cells from malignant B cells in patients with CLL. A study 
showed  that  a  unique  miRNA  signature  is  associated  with 
p r o g n o s t i c  f a c t o r s  a n d  d i s e a s e  p r o g r e s s i o n  i n  C L L  ( 1 2 4 ) .  
Acute myeloid leukemia (AML) carrying NPM1 mutations and 
cytoplasmic nucleophosmin (NPMc＋AML) accounts for about 
one-third of adult AML and shows distinct feature, including 
a unique gene expression profile (112). Garzon et al. inves-
t i g a t e d  t h e  r o l e  o f  m i R N A  i n  t h e  b i o l o g y  o f  N P M c ＋AML 
(112).  They  identified  a  strong  miRNA  signature  that  dis-
tinguishes  NPMc＋mutated  from  the  cytoplasmic-negative 
(NPM1  unmutated)  cases  and  induces  the  up-regulation  of 
miR-10a, miR-10b, several let-7 and miR-29 family members 
and  that  many  of  the  down-regulated  miRNAs  including 
miR-204  and  mmiR-128a  are  predicted  to  target  several 
Homebox  (HOX)  gene  (112).  They  also  confirmed  that 
miR-204 targets HOXA10 and MEIS1, suggesting that the HOX 
up-regulation observed in NPMc＋AML may be due in part 
by loss of HOX regulators-miRNAs (112). Further experiments 
demonstrated  that  the  up-regulation  of  miR-155  was  in-
dependent  from  FLT3  signaling .  T h e s e  r e s u l t s  i d e n t i f y  a  
unique  miRNA  signature  associated  with  NPMc＋AML  and 
provide evidence that support a role for miRNAs in the regu-
lation  of  HOX  genes  in  this  leukemia  subtype  (112).  It  is 
known that aberrant miRNA expression can play a vital role 
in  the  pathology  of  leukemia,  thus  miRNAs  have  rapidly 
emerged  as  potential  targets  for  therapeutics  (127).  Recent 
studies showed the important roles of miRNAs in the patho-
genesis of leukemia, including AML, acute lymphoblastic leu-
kemia (ALL), chronic myeloid leukemia (CML) and CLL (127).
HODGKIN LYMPHOMA 
Currently, Navrro et al. analyzed miRNA expression in classic 
Hodgkin  lymphoma  and  found  that  miR-96,  miR-128,  and 
miR-128b were selectively down-regulated in classic Hodgkin 
l y m p h o m a  w i t h  E p s t e i n - B a r  v i r u s ,  s u g g e s t i n g  t h a t  m i R N A s  
play an important role in the biology of classic Hodgkin lym-
phoma and may be useful in developing therapies targeting 
miRNAs  (28).
    The  discovery  of  hundreds  of  distinct  regulatory  miRNAs 
has already led to profound changes in our understanding of 
the  genetic  control  mechanisms  that  operate  in  health  and 
disease (65,66). By now, dozens of miRNAs have been re-
ported  in  various  tumor  phenotypes  as  described,  and  yet 
these only scratch the surface of the real complexity, as the 
functions of hundreds of miRNAs known to be present in our 
cells  and  altered  in  expression  in  different  forms  of  cancer 
r e m a i n  t o t a l  m y s t e r i e s  ( 6 6 ) .  H e r e  a g a i n ,  w e  a r e  u n c l e a r  a s MicroRNAs in Human Cancers and Heart Disease
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to  whether  future  progress will  cause  fundamental  shifts  in 
our understanding of the pathogenetic mechanisms of cancer 
or  only  add  detail  to  the  elaborate  regulatory  circuits  that 
h a v e  a l r e a d y  b e e n  m a p p e d  o u t  ( 6 6 ) .  
CARDIOVASCULAR DISEASES
Cardiovascular  disease  is  the  predominant  cause  of  human 
morbidity and mortality in developed countries. Thus, extra-
ordinary effort has been devoted to determining the molec-
ular  and  pathophysiological  characteristics  of  the  diseased 
heart and vasculature with the goal of developing novel diag-
nostic and therapeutic strategies to combat cardiovascular dis-
ease  (28).  Recently,  miRNAs  are  implicated  in  the  patho-
genesis of various cardiovascular diseases and have become 
an  intriguing  target  for  therapeutic  intervention  (5,91,128).
    Congestive heart failure is a growing problem that reduce 
life  span  and  lowers  the  quality  of  life  of  those  it  afflicts. 
Congestive heart failure is characterized by neurohumoral ac-
t i v a t i o n  a n d  a  d e c l i n e  i n  c a r d iac  output  (129,130).  Several 
miRNAs are regulated uniformly across all causes of heart fail-
ure and miRNA regulate embryogenesis and cell fate determi-
nation  (5,91,128).  Without  Dicer,  mice  die  in  utero  ∼7.5 
days  after  fertilization  (129,131).  It  has  been  reported  that 
miRNAs  regulate  cardiovascular  structure  and  function  (5). 
Interestingly, miRNAs promote the commitment of embryonic 
stem  cells  to  the  cardiomyocyte  lineage  and  cardiomyocyte 
differentiation  and  proliferation  require  temporal  and  tran-
scription regulation of specific genetic programs (129,131). In 
addition, miRNA also regulate genes important for ventricular 
hypertrophy (129). Importantly, the cardiac-specific miRNAs 
(miR-1, miR-133, and miR-208) participate in the development 
o f  v e n t r i c u l a r  h y p e r t r o p h y  a n d  h e a r t  f a i l u r e  ( 9 1 , 1 2 9 ) .  
Over-expression of miR-133 blocked cardiac hypertrophy in 
Akt transgenic mice (129). The accumulating experimental re-
sults clearly show that miRNAs play a significant role in car-
diovascular development and  disease, and  that miRNAs  are 
important for regulating cardiomyocytes self-renewal and dif-
ferentiation, as well as for normal cardiac structural integrity 
(128,129,131). Identification of those miRNA and target genes 
that  contribute  adult  cardiac  pathology  is  likely  to  suggest 
new  target  for  therapy.
    Atherosclerotic coronary artery disease (CAD) continues to 
be  an  important  socioeconomic  problem  and  the  leading 
cause  of  death  in  the  developing  countries  (29).  Major  in-
dependent risk factors for CAD are known to include familiar-
ity, high blood cholesterol levels, hypertension, smoking, dia-
betes,  and  obesity  (29).  Innovative  early  and  reliable  bio-
m a r k e r  a n d  t h e r a p e u t i c  t a r g e t s  f o r  C A D  w o u l d  t h u s  b e  a c-
claimed (29). Recently, miRNAs were found to be present in 
the circulating bloodstream and it was discovered that plasma 
and serum miRNAs posses robust stability even after cycles 
of  freezing/thawing  (132-135).  Moreover,  acute  myocardial 
infarction (AMI) is the world’s leading cause of morbidity and 
mortality (6). More recent reports showed that after AMI in 
humans and mice, muscle-enriched miRNAs, such as miR-1, 
miR-133a, miR-133b, and miR-499-5p, are increased in plasma 
and that miR-499 and miR-133a are highly expressed in heart, 
whereas  miR-1  and  miR-133a  are  highly  expressed  both  in 
heart and in skeletal muscel (6,29). Indicating that circulating 
miRNAs may become helpful and reliable tools for the diag-
nosis ad prognosis of patients with CAD or other cardiova-
scular disease. As mentioned, miR-21 is aberrantly expressed 
in multiple types of cancer including advanced human breast 
cancer,  cervical  and  ovarian  cancer,  colon  carcinoma,  hep-
atocellular cancer, glioma, esophageal cancer, B-cell lympho-
ma, prostate cancer, lung cancer and other cancer types but 
also  in  cardiovascular  disease  (91).  The  consistent  miR-21 
overexpression under pathophysiological conditions points to 
miR-21 as a valuable tool for new therapeutic strategies (91).
    Various miRNAs are expressed in a tissue-specific manner, 
and, thus may regulate tissue-specific functions. Recently, a 
number  of  miRNAs  have  been  found  to  be  striated-muscle 
specific (such as miR-1 and miR-133), whereas only miR-208 
has been found to be purely cardiac specific (136). Several 
recent  studies  performed  microarray  analysis  to  determine 
whether miRNAs are dysregulated in hypertrophic and failing 
hearts (5,91,136,137). These studies have revealed signature 
patterns of miRNAs that are up- and down-regulated during 
pathological  cardiac  remodeling  in  rodents  and  humans 
(5,91,136,137).  Although  miR-1,  miR-29,  miR-30,  miR-133, 
and miR-150 have often been found to be down-regulated, 
however, miR-21, miR-23a, miR-125, miR-195, miR-199, and 
m i R - 2 1 4  a r e  u p - r e g u l a t e d  w i t h   hypertrophy  (5,91,136,137). 
Gain-and  loss-of-function  studies  have  implicated  these 
miRNAs in the different aspects of remodeling process during 
the  progression  of  heart  disease  (5,137).
    The continuous discovery of new miRNAs suggest that the 
present collection of miRNAs implicated in cardiovascular dis-
ease is likely to be incomplete. In diseased hearts, regional 
changes  in  electrophysiology  can  result  in  nonuniform  im-
p u l s e  p r o p a g a t i o n ,  w h i c h  c a n  l e a d  t o  a r r h y t h m i a s  ( 5 , 1 3 6 ) .  MicroRNAs in Human Cancers and Heart Disease
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Although arrhythmias usually develop as a result of cardiac 
disease or inherited gene mutations in ion channel, several 
miRNAs,  including  miR-1  and  miR-133,  have  recently  been 
implicated in electophysiological abnormalities (5,136). Ikeda 
et al. compared miRNA expression in 3 different types of hu-
man  heart  disease  (ischemic  cardiomyopathy,  dilated  car-
diomyopathy,  and  aortic  stenosis)  with  normal  heart  (137). 
Among  the  87  miRNAs  detected  in  the  heart,  roughly  half 
w e r e  d i f f e r e n t i a l l y  e x p r e s s e d  i n  a t  l e a s t  1  d i s e a s e  g r o u p ,  
whereas 7 miRNAs were regulated in the same direction in 
all 3 disease states (137). Especially intriguing is the discovery 
o f  a  n e t w o r k  o f  m u s c l e - s p e c i f i c  m i R N A s  e m b e d d e d  w i t h i n  
myosin heavy chain genes, which control myosin expression 
and the response of the heart to stress and thyroid hormone 
signaling  (138).
    Thioredoxin  1  (Trx1)  is  a  ubiquitously  expressed  anti-
oxidant that has 2 cystine residues in its catalytic center and 
one  of  the  most  prominent  actions  of  Trx1  in  the  heart  is 
suppression of cardiac hypertrophy (139). Currently, a study 
investigated the role of miRNAs in mediating the anti-hyper-
trophic effect of Trx1 on angiotensin II (AngII)-induced car-
diac hypertrophy (139). The authors found that Trx1 up-regu-
lates expression of the let-7 family, including miR-98, which 
in  turn  inhibits  cardiac  hypertrophy,  in  part  through 
down-regulation  of  cyclin  D2  (139).
    AMI involves necrotic and apoptotic loss of cardiomyocytes 
and  one  strategy  to  salvage  ischemic  cardiomyocytes  is  to 
modulate  gene  expression  to  promote  cell  survival  without 
disturbing normal cardiac function (30). Currently, Qian et al. 
reported that miR-24 expression is down-regulated in the is-
chemic  border  zone  of  the  murine  left  ventricle  after  AMI 
(30). The authors also reported that miR-24 suppresses car-
diomyocyte  apoptosis,  in  part  by  direct  repression  of  the 
BH3-only  domain-containing  protein  Bim,  which  positively 
regulates apoptosis and that in vivo expression of miR-24 in 
a mouse AMI model inhibited cardiomyocyte apoptosis, atte-
nuated  infarct  size,  and  reduced  cardiac  dysfunction  (30). 
Interestingly,  this  antiapoptotic  effect  on  cardiomyocytes  in 
vivo was partially mediated by Bim (30). These results sug-
gest  that  manipulating  miRNA  levels  during  stress-induced 
apoptosis  may  be  a  novel  therapeutic  strategy  for  cardiac 
disease. 
    Courboulin et al. also currently reported that miR-204 ex-
pression  in  pulmonary  artery  smooth  muscle  cells  is 
down-regulated in both human and rodent pulmonary arterial 
hypertension (PAH) and that miR-204 down-regulation corre-
lates with PAH severity (140). Importantly, they also reported 
that delivery of synthetic miR-204 to the lungs of animals with 
PAH significantly reduced disease severity, suggesting that re-
establishing miR-204 expression should be explored as a po-
tential  new  therapy  for  this  disease.  miR-133,  which  is  en-
riched in cardiac and skeletal muscle, is involved in cell spec-
ification,  differentiation,  and  development  (141).  It  is  also 
down-regulated during cardiac hypertrophy, which indicated 
that it may play a role in the underlying pathogenesis (141).
CONCLUSION REMARKS
Accumulating  evidence  has  demonstrated  that  microRNAs 
(miRNAs) play a major role in a wide range of developmental 
processes including cell proliferation, cell differentiation, cell 
cycle, metabolism, apoptosis, developmental timing, neuronal 
cell  fate,  neuronal  gene  expression,  brain  morphogenesis, 
muscle  differentiation  and  stem  cell  division.  In  addition, 
miRNAs could contribute to pathogenesis of many diseases. 
Aberrant miRNA function influences human disease. It is in-
teresting to note that some miRNAs may have dual functions 
as both tumor suppressors and oncogenes. Moreover, a large 
number of studies have reported link between alteration of 
miRNA homeostasis and pathological conditions such as psy-
chiatric  and  neurological  diseases  as  well  as  cancer,  car-
diovascular diseases and autoimmune diseases. Furthermore, 
miRNA deficiencies or excess have been reported to be corre-
lated with a number of clinically important  disease  ranging 
from infection and myocardial infarction to cancer. Importan-
tly, relatively small changes in miRNA expression can lead to 
modest changes in the levels of multiple genes within bio-
logical network, and collectively these can add up to large 
changes  in  biology.  Therefore,  it  is  not  surprisingly  that 
miRNAs have been implicated in various human diseases. In 
t h i s  r e v i e w ,  I  s u m m a r i z e d  t h e  n e w l y  d i s c o v e r e d  r o l e s  o f  
miRNAs in various human cancers and cardiovascular diseases. 
    In the future, distinct miRNA signature involved in cancers 
should  define  the  role  of  miRNA  in  biochemical  and  bio-
logical  processes.  Furthermore,  identification  of  miRNAs  of 
significance in disease could provide rationale for the design 
and implementation of disease classification, early detection, 
disease prognosis and therapeutic decision making, and other 
new  immunotherapeutic  and  pharmacological  strategies  for 
treatment of diseases. Moreover, miRNAs may represent at-
tractive novel diagnostic biomarkers mainly due to their high-
er  stability  when  compared  to  RNAs  and  could  potentially MicroRNAs in Human Cancers and Heart Disease
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provide possibilities for therapeutic intervention. Unravelling 
the regulatory circuits of miRNAs in biology is still in its in-
fancy,  but  will  likely  yield  new  insights  into  our  under-
standing  of  immunophysiology  and  immunopathology.  It  is 
hoped that research into the normal biochemical process will 
dovetail with a better understanding of the pathological proc-
e s s  t h a t  t h e s e  m o l e c u l e s  a n d  p a t h w a y  p l a y .
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